In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PIramed Ltd.

Executive Summary

PIramed Ltd. was incorporated in October 2001 to commercialize the findings of a research collaboration between three of Europe's leading cancer research institutes (the Ludwig Institute for Cancer Research, Cancer Research UK and the Institute for Cancer Research) and Yamanouchi Pharmaceutical Co. Ltd. The collaboration, initiated in 1995, identified a range of small molecule inhibitors of the PI3 Kinase (PI3K) family of lipid kinases-intracellular enzymes that are important in cell signalling pathways that influence a range of fundamental cellular activities including growth, migration, proliferation and survival, and are implicated in a number of diseases, including cancer, cardiovascular, neurodegenerative and immune-inflammatory diseases.
Advertisement

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004812

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel